1.Department of Nephrology, the First Affiliated Hospital of Nanjing Medical University Jiangsu Provincial Hospital, Jiangsu Province, Nanjing 210029, China; 2.Department of Nephrology, Wuhu Second People’s Hospital, Anhui Province, Wuhu 241000, China
Abstract：Objective To observe the clinical effect of Calcitriol on early type 2 diabetic nephropathy. Methods A total of 90 type 2 diabetic nephropathy patients admitted to the First Affiliated Hospital of Nanjing Medical University and the Wuhu Second People’s Hospital from August 2019 to May 2022 were selected as the study objects, and they were divided into two groups by random number table method， with 45 cases in each group. The control group received Olmesartan Ester on the basis of conventional treatment, and the observation group received Calcitriol on the basis of the control group, the treatment course of both groups was eight weeks. Renal function (serum creatinine [Scr], urinary albumincreatinine ratio [UACR], microalbuminuria [MA], cystatin C [CysC]), alkaline phosphatase (ALP), blood pressure (diastolic blood pressure [DBP], systolic blood pressure [SBP]), blood glucose (fasting blood glucose [FBG], glycated hemoglobin [HbA1c]), NADPH Oxidase 4 (NOX4) of the two groups were compared before and after treatment, the efficacy and incidence of adverse reactions were compared between the two groups. Results After treatment, Scr, UACR, MA, CysC in both groups, and ALP in control group were lower than those before treatment, and Scr, UACR, MA, CysC in observation group were lower than those in control group (P＜0.05). The ALP in the observation group was higher than that before treatment, and the observation group was higher than that in the control group (P＜0.05). After treatment, SBP, DBP, FBG and HbA1c in both groups were decreased compared with those before treatment (P＜0.05), and there was no statistical significance between groups (P＞0.05). After treatment, urine NOX4 decreased in both groups compared with that before treatment, and the observation group was lower than the control group (P＜0.05). The efficacy of the observation group was better than that of the control group(P＞0.05). There was no significant difference in the total rate of adverse reactions between the two groups (P＞0.05). Conclusion Calcitriol in the treatment of early type 2 diabetic nephropathy patients can significantly reduce the renal function damage, the degree of interphase podocyte damage, and improve the efficacy.
2023, Vol. 20 
京公网安备 11010502046598号